Cargando…

Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study

BACKGROUND: Immune checkpoint inhibitors have demonstrated efficacy in the treatment of classical Hodgkin’s lymphoma (cHL). We analyzed the efficacy and safety of pembrolizumab or nivolumab in patients with pretreated cHL. METHODS: Clinical data from the cancer chemotherapy registry of Samsung Medic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hur, Joon Young, Yoon, Sang Eun, Kim, Seok Jin, Kim, Won Seog
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343550/ https://www.ncbi.nlm.nih.gov/pubmed/32595170 http://dx.doi.org/10.5045/br.2020.2020014

Ejemplares similares

Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing
por: Cho, Junhun, et al.
Publicado: (2021)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

A Review of Hodgkin Lymphoma in the Era of Checkpoint Inhibitors
por: Schimmoeller, Christopher J, et al.
Publicado: (2023)

Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma
por: Bang, Yeong Hak, et al.
Publicado: (2022)

Clinical manifestations of autoimmune disease-related non-Hodgkin lymphoma: a Korean single-center, retrospective clinical study
por: Jeon, Young-Woo, et al.
Publicado: (2016)

Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study
por: Lee, Seong Jun, et al.
Publicado: (2014)

A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B‐cell lymphoma
por: Lee, Hyunjee, et al.
Publicado: (2023)

Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma
por: Nakhoda, Shazia, et al.
Publicado: (2022)

Immune Checkpoint Inhibition in Hodgkin Lymphoma
por: Moy, Ryan H., et al.
Publicado: (2018)

Checkpoint inhibitor immunotherapy during pregnancy for relapsed–refractory Hodgkin lymphoma
por: Evens, Andrew M., et al.
Publicado: (2022)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

Usefulness of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases in Non-Hodgkin Lymphoma
por: Shin, Sang-Yong, et al.
Publicado: (2016)

Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study
por: Kang, Danbee, et al.
Publicado: (2021)

Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway
por: Zhang, Xiao-Yin, et al.
Publicado: (2022)

Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis
por: Lee, Yong-Pyo, et al.
Publicado: (2022)

Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma
por: Lin, Adam Yuh, et al.
Publicado: (2022)

Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review
por: Kim, Seok Jin, et al.
Publicado: (2018)

Pretreatment Cancer-Related Cognitive Impairment in Hodgkin Lymphoma Patients
por: Juríčková, Veronika, et al.
Publicado: (2023)

Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas
por: Shin, Sang-Yong, et al.
Publicado: (2016)

Prognostic role of pretreatment (18)F-FDG PET/CT and hematological parameters in relapsed/refractory Hodgkin lymphoma patients treated with immune checkpoint inhibitors and chemotherapy: a dual-center cohort study
por: Yang, Tianyu, et al.
Publicado: (2023)

Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study
por: Kang, Danbee, et al.
Publicado: (2018)

Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma
por: Apostolidis, John, et al.
Publicado: (2020)

Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors
por: Joshi, Maansi, et al.
Publicado: (2020)

Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors
por: Argnani, Lisa, et al.
Publicado: (2022)

Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study
por: Hur, Joon Young, et al.
Publicado: (2019)

Langerhans Cell Histiocytosis Followed by Hodgkin's Lymphoma
por: Park, IK Soo, et al.
Publicado: (2012)

Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party
por: Suh, Cheolwon, et al.
Publicado: (2013)

Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma
por: Li, Wenchao, et al.
Publicado: (2018)

Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
por: De Re, Valli, et al.
Publicado: (2019)

Checkpoint CD47 expression in classical Hodgkin lymphoma
por: Gholiha, Alex Reza, et al.
Publicado: (2022)

Asian variant of intravascular large B-cell lymphoma: a comparison of clinical features based on involvement of the central nervous system
por: Yoon, Sang Eun, et al.
Publicado: (2020)

The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
por: Heo, Ja Yoon, et al.
Publicado: (2019)

Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months
por: Yoon, Sang Eun, et al.
Publicado: (2021)

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas
por: Kim, Seok-Jin, et al.
Publicado: (2019)

Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma
por: Kang, Ka-Won, et al.
Publicado: (2018)

PARP-1 Val762Ala polymorphism is associated with reduced risk of non-Hodgkin lymphoma in Korean males
por: Jin, Xue Mei, et al.
Publicado: (2010)

Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma
por: Maeng, Chi Hoon, et al.
Publicado: (2017)

ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin's Lymphoma: A Single Center Experience
por: Park, Sang Hyoung, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_7iljd9pf9mkjuhgins18sni24g